UNSPSC 51123702: Tedisamil

This classification denotes an antiarrhythmic agent with the molecular formula C19H32N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) A5VAY2U3R8, chemically known as 3,7-bis(cyclopropylmethyl)spiro(cyclopentane-1,9-(3,7)diazabicyclo(3.3.1)nonane) but more generally known as tedisamil, which bears US NIH Compound Identifier 65825. European Medicines Agency schedules Tedisamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10864MIG.

UNSPSC 51123702 Tedisamil is a Commodity code that covers pharmaceutical active pharmaceutical ingredients and finished medications used in clinical and emergency medical settings. State and local governments procure under this code primarily to supply emergency medical services, hospital systems, and public health programs with specific pharmaceutical products, often through sealed competitive bidding processes. The code encompasses finished medications in injectable and oral forms that serve acute care and life-support functions, including vasopressors, antiarrhythmics, and hemodynamic agents. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across state and local facilities.

Recent activity reflects geographic spread across the South and Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for advanced life support medications (Labetalol HCI, Epinephrine 1:10,000, Adenosine, and Diltiazem) to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with a response deadline of March 26, 2026; awards require cGMP and DSCSA compliance, insurance coverage including $5,000,000 general liability, and distribution through AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer pharmacy benefit programs, signaling potential future demand for vendors capable of direct contracting with state agencies outside traditional wholesaler channels.